Wells Fargo & Company Beyond Spring Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Beyond Spring Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 580 shares of BYSI stock, worth $991. This represents 0.0% of its overall portfolio holdings.

Number of Shares

580

Previous 580 -0.0%

Holding current value

$991

Previous $1,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.06 - $3.05 $2,120 - $6,100	-2,000 Reduced 77.52%	580 $0
Q4 2022 Feb 13, 2023	BUY	$0.56 - $2.61 $1,120 - $5,220	2,000 Added 344.83%	2,580 $4,000
Q3 2022 Nov 14, 2022	SELL	$0.97 - $1.81 $533 - $995	-550 Reduced 48.67%	580 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.13 - $2.66 $14,826 - $34,901	-13,121 Reduced 92.07%	1,130 $2,000
Q1 2022 May 16, 2022	BUY	$1.68 - $5.01 $1,461 - $4,358	870 Added 6.5%	14,251 $31,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $33,848 - $141,792	8,420 Added 169.72%	13,381 $61,000
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $22,409 - $75,770	2,420 Added 95.24%	4,961 $78,000
Q2 2021 Aug 16, 2021	SELL	$9.37 - $12.12 $54,477 - $70,465	-5,814 Reduced 69.59%	2,541 $27,000
Q1 2021 May 13, 2021	SELL	$10.61 - $15.77 $368,464 - $547,660	-34,728 Reduced 80.61%	8,355 $92,000
Q4 2020 Feb 09, 2021	BUY	$10.21 - $17.31 $3,971 - $6,733	389 Added 0.91%	43,083 $526,000
Q3 2020 Nov 05, 2020	SELL	$9.99 - $16.13 $34,435 - $55,600	-3,447 Reduced 7.47%	42,694 $569,000
Q2 2020 Aug 13, 2020	BUY	$11.21 - $18.15 $160,258 - $259,472	14,296 Added 44.89%	46,141 $695,000
Q1 2020 May 14, 2020	BUY	$9.68 - $18.47 $308,259 - $588,177	31,845 New	31,845 $408,000

Others Institutions Holding BYSI

# of Institutions

Shares Held

5.55M

Call Options Held

26K

Put Options Held

2.4K

View Full List

About BeyondSpring Inc.

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $66.6M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

More about BYSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Beyond Spring Inc. Transaction History